Sanofi v Amgen Inc. (No 2)

Link copied
Case Copied 16 min read

FEDERAL COURT OF AUSTRALIA

Sanofi v Amgen Inc. (No 2) [2023] FCA 1156   

File number: NSD 876 of 2022
Judgment of: YATES J
Date of judgment: 22 September 2023
Date of publication of reasons: 27 September 2023
Catchwords: PRACTICE AND PROCEDURE – patents – appeal from decision of a delegate of the Commissioner of Patents in opposition proceedings – application seeking orders pursuant to r 5.04 of the Federal Court Rules 2011 (Cth) limiting evidence to be relied on at the hearing of the appeal – where respondent intends to tender declarations relied on before the delegate together with affidavits made by the same declarants – where the affidavits summarise statements made in the declarations
Legislation:

Evidence Act 1995 (Cth) ss 135, 136

Federal Court Rules 2011 (Cth) rr 5.04, 34.31

Patents Act 1990 (Cth) s 160

Patents Regulations 1991 (Cth) reg 5.23

Cases cited: Novartis AG v Pharmacor Pty Ltd [2022] FCAFC 58; 290 FCR 345
Division: General Division
Registry: New South Wales
National Practice Area: Intellectual Property
Sub-area: Patents and associated Statutes
Number of paragraphs: 43
Date of hearing: 21 September 2023
Counsel for the Applicant: Mr D Shavin KC and Ms K Beattie
Solicitor for the Applicant: Jones Day
Counsel for the Respondent: Mr T Cordiner KC and Ms M McGrath
Solicitor for the Respondent: Wrays Lawyers Pty Ltd

ORDERS

NSD 876 of 2022
BETWEEN:

SANOFI

Applicant

AND:

AMGEN INC.

Respondent

ORDER MADE BY:

YATES J

DATE OF ORDER:

22 SEPTEMBER 2023

THE COURT ORDERS THAT:

1.The interlocutory application dated 1 September 2023 be dismissed.

2.The applicant pay the respondent’s costs of and incidental to the interlocutory application.

Note:   Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.


REASONS FOR JUDGMENT

YATES J:

INTRODUCTION

  1. By an interlocutory application dated 1 September 2023, the applicant, Sanofi, who is the appellant in the principal proceeding, seeks orders pursuant to r 5.04 of the Federal Court Rules 2011 (Cth) (the Rules) limiting the evidence which the respondent, Amgen Inc., can adduce at the hearing of this proceeding.

  2. The proceeding is an appeal from a decision of a delegate of the Commissioner of Patents (the delegate) in opposition proceedings.  The respondent is the applicant named in Patent Application Nos.  2013203677, 2013203685, 2013203689, 2013203748, and 2013203751 (the patent applications).

  3. The appeal is a hearing de novo in which the applicant bears the onus of making out its grounds of opposition.  The applicant has raised a significant number of grounds of opposition, including an additional ground (lack of inventive step) that was not raised in the opposition before the delegate.  The amended notice of appeal is complex and lengthy (79 pages).

  4. The hearing of the proceeding is listed to commence on 6 November 2023.

    BACKGROUND

  5. The claims of the patent applications are directed to, amongst other subject matter, isolated monoclonal anti-PCSK9 antibodies that have particular features.  The claims in three of the patent applications are directed to isolated monoclonal antibodies that bind…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Sanofi v Amgen Inc. (No 2) and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2023] FCA 1156
Decision Date

CaseChat Overview and Summary

Sanofi v Amgen Inc. (No 2) involved a patent dispute where Sanofi, the applicant, appealed a decision made by a delegate of the Commissioner of Patents in opposition proceedings. The patent in question pertained to isolated monoclonal anti-PCSK9 antibodies, specifically those that bind to certain residues on the PCSK9 protein and inhibit its interaction with the LDL receptor. The appeal focused on the admissibility of evidence, particularly the declarations made by expert witnesses in the opposition proceedings and the affidavits that summarised these declarations.

The legal issue before the court was whether the respondent, Amgen Inc., could rely on affidavits that summarised the declarations of expert witnesses when the court had previously allowed both parties to rely on the declarations from the opposition proceedings. The applicant argued that the summarising of the declarations created uncertainty and potentially duplicated evidence, which they claimed was a failure to comply with the procedural orders. The court had to decide whether this constituted a breach of the orders or if it was an acceptable form of evidence presentation.

Nicholas J held that summarising the declarations in the affidavits did not amount to a failure to comply with the procedural orders. The judge noted that the affidavits could serve as context for additional evidence or as introductions for revised evidence that addressed potential admissibility objections. The judge also pointed out that if the applicant believed that the summarising raised admissibility issues, they could object at the appropriate time. Moreover, the trial judge retained the authority to manage the admissibility of evidence under the Evidence Act 1995 (Cth). The court concluded that the applicant had not demonstrated any grounds that warranted the granting of the relief sought, and the interlocutory application was dismissed with costs awarded to the respondent.

The court's decision underscored the importance of adhering to procedural orders while also allowing flexibility in evidence presentation. It highlighted that changes in the course of action based on convenience alone were insufficient to warrant a revisitation of previously granted leave. The court's ruling ensured that the proceedings would continue with the experts participating in their respective discussions, preparing a joint report to clarify areas of agreement and disagreement.

Orders

Orders of the court

1. The interlocutory application dated 1 September 2023 be dismissed.

2. The applicant pay the respondent’s costs of and incidental to the interlocutory application.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

The hearing of the proceeding is listed to commence on 6 November 2023.BACKGROUND The claims of the patent applications are directed to, amongst other subject matter, isolated monoclonal anti-PCSK9 antibodies that have particular features. The claims in three of the patent applications are directed to isolated monoclonal antibodies that bind to one or more specific residues, or an epitope comprising one or more specific residues, on the PCSK9 protein and block the protein’s interaction with the LDL receptor. Other claims in the patent applications are directed to isolated anti-PCSK9 monoclonal antibodies that compete with a specific reference antibody, and block PCSK9’s interaction with the LDL receptor. The patent applications disclose: (a) a number of specialised techniques for the production of monoclonal antibodies and various assays relating to their function and characteristics (which fall within the field of those with expertise in antibodies); and (b) techniques for the characterisation of protein:protein interactions, such as x-ray crystallography (which fall within the field of those with expertise in structural biology/crystallography). The patent applications discuss multiple methods by which the antibodies of the invention can be generated, including phage display and hybridoma technology. Before the delegate, the applicant raised a number of grounds of opposition and relied on a number of declarations made by Professor Stephen Mahler (an expert in antibodies) and Professor Michael Parker (an expert in structural biology and crystallography) in chief and in reply. The respondent relied on declarations made by Professor Angel Lopez (an expert in antibodies with particular expertise in hybridoma technology for the production of antibodies) and Professor Gregory Petsko (an expert in structural biology and crystallography). The respondent also relied on a declaration made by Professor Peter Hudson. Professor Hudson has experience in structural biology and crystallography as well as in antibodies (with particular expertise in phage display technology for the production of antibodies). Professor Hudson was the respondent’s only expert who addressed particular evidence given by Professor Parker. In addition, the respondent relied on declarations made by Professor Hudson and Professor Lopez that were filed under reg 5.23 of the Patents Regulations 1991 (Cth). In response, the applicant also relied on declarations made by Professor Parker. The notice of appeal was filed on 17 October 2022. The proceeding came before the docket judge, Nicholas J, for a case management hearing on 24 November 2022. At the case management hearing, the question of whether the parties intended to rely on the declarations that were before the delegate was addressed. At that time, both parties advanced draft orders that permitted them to rely on those declarations. The respondent also informed the Court that it intended to call evidence from the same witnesses—Professor Lopez, Professor Petsko, and Professor Hudson.

Evidence

Evidence Before The Court

On 30 November 2022, Nicholas J made orders which included the following orders:Evidence1.Each party has leave to tender any declaration filed by that party in the opposition proceedings subject to all proper objections and the deponent being available to give oral evidence if so ordered.2.The appellant is to file and serve by 28 April 2023 a written notice specifying which declarations, or parts of declarations, it will tender at the hearing.3.The respondent is to file and serve by 28 July 2023 a written notice specifying which declarations, or parts of declarations, it will tender at the hearing.4.Any additional written evidence on which either party seeks to rely at the hearing be given by affidavit filed and served in accordance with these orders. 5.Each party is granted leave to file and serve any affidavit made by any witness who has made a declaration referred to in order 1 which includes any supplementary evidence not included in the witness’ declaration upon which the party will seek to rely at the hearing.6.Any affidavit on which the appellant will seek to rely pursuant to order 5 must be filed and served by 28 April 2023.7.Any affidavit on which the respondent will seek to rely pursuant to order 5 must be filed and served by 28 July 2023.8.If the appellant seeks to rely at the hearing on any written evidence in chief from any witness who did not make a declaration referred to in order 1 then it must file and serve an affidavit made by that witness by 28 April 2023.9.If the respondent seeks leave to rely at the hearing on any written evidence in answer from any witness who did not make a declaration referred to in order 1 then it must file and serve an affidavit made by that witness by 28 July 2023.10.For the avoidance of doubt, orders 2–9 (inclusive) are not orders under s 160(a) of the Patents Act 1990 (Cth). What orders should be made pursuant to s 160(a) will be the subject of consideration at a later date. On 1 May 2023, the applicant filed affidavits by Professor Mahler and Professor Parker. The applicant also gave notice of the declarations and parts of declarations of Professor Mahler and Professor Parker which it intended to tender at the hearing of the appeal. The applicant said that it would tender: (a) all the declarations made by Professor Mahler and Professor Parker that had been filed as the applicant’s evidence in support; (b) certain paragraphs of the declarations of Professor Mahler and Professor Parker that had been filed as the applicant’s evidence in reply; and (c) certain paragraphs of the declarations made by Professor Parker that had been filed under reg 5.23. On 4 August 2023, the respondent gave notice that it intended to rely on the declarations made by Professor Petsko, Professor Lopez, and Professor Hudson that it had filed as the respondent’s evidence in answer to the applicant’s evidence in support. The respondent has also filed two affidavits made by Professor Petsko, one affidavit made by Professor Hudson, and one affidavit made by Professor Lopez. The respondent says that these affidavits are intended to: (a) supplement the evidence given by the deponents in their declarations (including by clarifying certain statements made in the declarations); (b) respond to statements made by Professor Parker and Professor Mahler in their affidavits filed on 1 May 2023; and (c) address anticipated objections to admissibility of some statements made in the declarations on which the respondent proposes to rely.

Decision

Reasons for decision

While I accept that the affidavits given by the respondent’s witnesses involve “summarising”, I accept the respondent’s submission that this might be justified (I say no more) as providing context in which additional evidence is to be advanced or as providing the necessary introduction for revised evidence that seeks to overcome previous deficiencies that might found an objection on admissibility grounds. There may well be other reasons why “summarising” might be permitted. If, however, the applicant considers that particular “summarising” gives rise, itself, to an objection on admissibility grounds, then the applicant can make its objection at the appropriate time. It is also open to a trial judge to utilise the powers under ss 135 and 136 of the Evidence Act 1995 (Cth) in an appropriate case. The point of present importance is that “summarising” of the kind identified by the applicant is not a failure to comply with the procedural orders that have been made.CONCLUSION AND DISPOSITION The applicant has not made out any ground that justifies the granting of the relief it seeks. The interlocutory application should be dismissed with costs.

Ratio Decidendi

Legal Principle Established

This leads to the applicant’s second complaint which is that, in their respective affidavits, Professor Petsko, Professor Lopez, and Professor Hudson adopt the technique of “summarising” statements made in their declarations. The applicant contends that, by preparing affidavits in this form, the respondent has disregarded the orders made on 30 November 2022 and created “real uncertainty” as to the evidence on which it relies. According to the applicant, there is a “disconformity” between the declarations and the affidavits because: (a) some declarations are not referred to in some affidavits; (b) some affidavits do not address some matters addressed in the declarations; and (c) some affidavits do not respond to the applicant’s evidence where the declarations do respond to that evidence. The applicant contends that, by summarising aspects of the declarations, the deponents have “duplicated” or “recast” their evidence leaving it uncertain as to whether the summary, or the part of the declaration said to have been summarised, stands as the deponent’s evidence. The applicant submits that this is embarrassing because it does not know which part of the respondent’s evidence it is required to respond to.CONSIDERATION I am not persuaded that the applicant raises any matter that would warrant the granting of the relief sought in the interlocutory application. Leaving to one side the applicant’s complaint about “summarising”, the problems it now raises (if they be problems) existed at the time of the first case management hearing in November 2022. At that hearing, the question of the parties’ desire to rely on the declarations deployed in the opposition hearing before the Commissioner’s delegate was specifically addressed. The applicant made no complaint about the number of expert witnesses that would be involved, or the duplication of evidence that would arise, if leave were to be granted to the parties to rely on those declarations, even though those matters must have been obvious to the applicant at that time, especially bearing in mind that the parties had already participated in a complex and lengthy hearing before the delegate. Nicholas J was obviously mindful of the extent of the evidence before the delegate but was nevertheless persuaded by the parties that it would be appropriate to grant them leave to rely on that evidence. This step has set the pattern for the filing of evidence in this appeal. Circumstances have not changed since that time except for the applicant’s apparent change of mind as to the appropriateness of the respondent having the benefit of the leave that was granted. A change of mind, however, is not a sufficient reason to revisit the grant of leave that was made, no matter how inconvenient the applicant might find its present position to be. I am far from persuaded that, in the present case, the applicant will suffer any actual or potential prejudice by the course that has been adopted to date. Whilst economy in the number of experts is always desirable, a particular course has been taken in the present case of permitting each party to rely on all the evidence given on its behalf in the opposition before the delegate if that party so chooses, subject to proper objections as to admissibility and the availability of the declarants for cross-examination. The parties having now made their elections, I perceive no problem in the appropriate experts participating in the appropriate conclaves and discussing their views on the matters on which they have been asked to opine with a view to preparing a joint report identifying and explaining (to the extent necessary) their areas of agreement and disagreement.